Sugi Predict

Sugi Predict / Targets / BRD3

BRD3

Bromodomain-containing protein 3 · Q15059 · BRD3 on Sugi Atlas →

67,521 patent compounds predicted against BRD3, 45,445 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL224361 SCHEMBL224361 0.61 19/20
SCHEMBL223599 SCHEMBL223599 0.56 19/20
SCHEMBL224890 SCHEMBL224890 0.56 19/20
SCHEMBL224891 SCHEMBL224891 0.56 19/20
SCHEMBL222873 SCHEMBL222873 0.54 19/20
SCHEMBL222924 SCHEMBL222924 0.50 19/20
SCHEMBL224065 SCHEMBL224065 0.58 18/20
SCHEMBL223065 SCHEMBL223065 0.53 18/20
SCHEMBL220739 SCHEMBL220739 0.51 18/20
SCHEMBL220740 SCHEMBL220740 0.51 18/20
SCHEMBL221491 SCHEMBL221491 0.66 17/20
SCHEMBL225875 SCHEMBL225875 0.66 17/20
SCHEMBL223799 SCHEMBL223799 0.64 17/20
SCHEMBL224292 SCHEMBL224292 0.64 17/20
SCHEMBL223665 SCHEMBL223665 0.60 17/20
SCHEMBL221283 SCHEMBL221283 0.56 17/20
SCHEMBL222018 SCHEMBL222018 0.56 17/20
SCHEMBL224960 SCHEMBL224960 0.56 17/20
SCHEMBL224961 SCHEMBL224961 0.56 17/20
SCHEMBL223323 SCHEMBL223323 0.55 17/20

Clinical trials — most relevant to BRD3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors PHASE1RECRUITING
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma PHASE1COMPLETED
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BRD3 binder may also engage these)

ProteinNameSimilarity
Q8K2F0 — 1.000 Q8K2F0 →
Q32S26 — 0.997 Q32S26 →
Q5TJG6 — 0.996 Q5TJG6 →
BRD2 Bromodomain-containing protein 2 0.995 landscape →
Q6MGA9 — 0.993 Q6MGA9 →
Q7JJ13 — 0.992 Q7JJ13 →
Q9ESU6 — 0.989 Q9ESU6 →
Q08D75 — 0.986 Q08D75 →
BRD4 Bromodomain-containing protein 4 0.986 landscape →
Q6DFF2 — 0.986 Q6DFF2 →
F1R5H6 — 0.985 F1R5H6 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.985 landscape →
Q8CGF7 — 0.984 Q8CGF7 →
Q3UQU0 — 0.982 Q3UQU0 →
Q9Y7N0 — 0.982 Q9Y7N0 →
SMARCC1 SWI/SNF complex subunit SMARCC1 0.981 landscape →
Q6PDG5 — 0.981 Q6PDG5 →
O75061 — 0.981 O75061 →
P97496 — 0.981 P97496 →
P35817 — 0.981 P35817 →
Q09YJ3 — 0.981 Q09YJ3 →
Q09YG9 — 0.981 Q09YG9 →
Q870Q1 — 0.981 Q870Q1 →
U2SURP U2 snRNP-associated SURP motif-containing protein 0.980 landscape →
Q2IBF8 — 0.980 Q2IBF8 →
Q17FR9 — 0.980 Q17FR9 →
Q8IWZ8 — 0.980 Q8IWZ8 →
Q2T9I5 — 0.980 Q2T9I5 →
Q8CJH2 — 0.980 Q8CJH2 →
Q32NW2 — 0.980 Q32NW2 →